Considerable progress is being made in the field of oncology, and the rapid expansion of available information can often make it difficult for the busy practitioner to know which decisions are most appropriate in a given circumstance. The success of the "Dana-Farber Cancer Institute Atlas of Diagnostic Oncology" has led to the development of a series of disease management handbooks designed to aid the clinician with his or her decision making in clinical practice. Written by highly eminent authors, each title is produced in full color and is richly illustrated throughout, providing a review of each cancer including its incidence, epidemiology, etiology and histopathology, together with the clinical features. Diagnostic studies and current clinical and pathological staging are also given. Detailed tables are provided with histopathological classification, diagnostic studies and, when important, prognostic factors. Current therapies are also discussed in detail, together with useful algorithms to aid treatment decisions.
Practical issues relating to management are also given such as dealing with systemic and mucocutaneous reactions to chemotherapy, including alopecia, fatigue and extravasation.
Buy Prostate Cancer book by Arthur T. Skarin from Australia's Online Bookstore, Boomerang Books.
(215mm x 133mm x 7mm)
Publisher: Elsevier Health Sciences
Country of Publication:
Author Biography - Arthur T. Skarin
Arthur T. Skarin, MD, FACP, FCCP, earned his MD from the State University of New York at Buffalo in 1961, and received postgraduate training in internal medicine at the Millard Fillmore Teaching Hospital in Buffalo. After a fellowship in hematology and oncology at Boston City Hospital, he joined Brigham and Women's Hospital and Dana-Farber Cancer Institute (DFCI) in 1970. He served as Clinical Director of the DFCI Hematology Laboratory as well as Chairman of the Laboratory Committee from 1970 to 1998. He established the multimodality thoracic oncology clinic in 1975 and has served as Medical Director since then. During that time he also was chair of the human protection committee (IRB) for 12 years and became Associate Professor of Medicine at Harvard Medical School. He has been the Principal Investigator (PI) as well as site PI on numerous clinical research Phase I, II and III trials, both at DFCI Partners Cancer Care and the Cancer and Leukemia Group B (CALGB). He was appointed a Research Subject Advocate (RSA) in 2002 for NIH funded studies at the Brigham and Women's Hospital General Clinical Research Center (GCRC) and DFCI. Dr. Skarin is a board member of the American Journal of Oncology Review, the Journal of Cinical Oncology, Hospital Physician and also president of the Massachusetts Society of Clinical Oncologists. He has published 150 original articles, 97 abstracts, 67 chapters in books and 4 books.